BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Simizu B, Abe S, Yamamoto H, Tano Y, Ota Y, Miyazawa M, Horie H, Satoh K, Wakabayashi K. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals 2006;34:151-4. [DOI: 10.1016/j.biologicals.2006.02.010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Bockstal V, Tiemessen MM, Achterberg R, Van Wordragen C, Knaapen AM, Serroyen J, Marissen WE, Schuitemaker H, Zahn R. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model. Vaccine 2018;36:6979-87. [PMID: 30314910 DOI: 10.1016/j.vaccine.2018.09.068] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Verdijk P, Rots NY, van Oijen MG, Weldon WC, Oberste MS, Okayasu H, Sutter RW, Bakker WA. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. Vaccine 2014;32:4938-44. [DOI: 10.1016/j.vaccine.2014.07.029] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
3 Tebbens RJ, Pallansch MA, Alexander JP, Thompson KM. Optimal vaccine stockpile design for an eradicated disease: application to polio. Vaccine 2010;28:4312-27. [PMID: 20430122 DOI: 10.1016/j.vaccine.2010.04.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
4 Westdijk J, Brugmans D, Martin J, Oever AV, Bakker WA, Levels L, Kersten G. Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines. Vaccine 2011;29:3390-7. [DOI: 10.1016/j.vaccine.2011.02.085] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
5 Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine 2016;34:1975-85. [PMID: 25448090 DOI: 10.1016/j.vaccine.2014.11.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
6 Verdijk P, Rots NY, Bakker WA. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Review of Vaccines 2014;10:635-44. [DOI: 10.1586/erv.11.51] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
7 Imura A, Sudaka Y, Takashino A, Tamura K, Kobayashi K, Nagata N, Nishimura H, Mizuta K, Koike S. Development of an Enterovirus 71 Vaccine Efficacy Test Using Human Scavenger Receptor B2 Transgenic Mice. J Virol 2020;94:e01921-19. [PMID: 31896594 DOI: 10.1128/JVI.01921-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Jiang R, Liu X, Sun X, Wang J, Huang Z, Li C, Li Z, Zhou J, Pu Y, Ying Z, Yin Q, Zhao Z, Zhang L, Lei J, Bao W, Jiang Y, Dou Y, Li J, Yang H, Cai W, Deng Y, Che Y, Shi L, Sun M. Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population. Vaccine 2021;39:1463-71. [PMID: 33487470 DOI: 10.1016/j.vaccine.2021.01.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Someya Y, Ami Y, Takai-Todaka R, Fujimoto A, Haga K, Murakami K, Fujii Y, Shirato H, Oka T, Shimoike T, Katayama K, Wakita T. Evaluation of the use of various rat strains for immunogenic potency tests of Sabin-derived inactivated polio vaccines. Biologicals 2018;52:12-7. [PMID: 29475730 DOI: 10.1016/j.biologicals.2018.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 Ehrenfeld E, Glass RI, Agol VI, Chumakov K, Dowdle W, John TJ, Katz SL, Miller M, Breman JG, Modlin J, Wright P. Immunisation against poliomyelitis: moving forward. Lancet 2008;371:1385-7. [PMID: 18424327 DOI: 10.1016/S0140-6736(08)60597-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
11 Liao G, Li R, Li C, Sun M, Li Y, Chu J, Jiang S, Li Q. Safety and Immunogenicity of Inactivated Poliovirus Vaccine Made From Sabin Strains: A Phase II, Randomized, Positive-Controlled Trial. The Journal of Infectious Diseases 2012;205:237-43. [DOI: 10.1093/infdis/jir723] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
12 Honda-Okubo Y, Baldwin J, Petrovsky N. Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines. Pathogens 2021;10:500. [PMID: 33919442 DOI: 10.3390/pathogens10050500] [Reference Citation Analysis]
13 Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 2007;25:7041-6. [DOI: 10.1016/j.vaccine.2007.07.060] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
14 Okada K, Miyazaki C, Kino Y, Ozaki T, Hirose M, Ueda K. Phase II and III Clinical Studies of Diphtheria-Tetanus-Acellular Pertussis Vaccine Containing Inactivated Polio Vaccine Derived from Sabin Strains (DTaP-sIPV). The Journal of Infectious Diseases 2013;208:275-83. [DOI: 10.1093/infdis/jit155] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
15 Tanaka Y, Yokokawa R, Rong HS, Kishino H, Stek JE, Nelson M, Lawrence J. Concomitant administration of diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine derived from Sabin strains (DTaP-sIPV) with pentavalent rotavirus vaccine in Japanese infants. Hum Vaccin Immunother 2017;13:1-7. [PMID: 28140752 DOI: 10.1080/21645515.2017.1279769] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hamidi A, Bakker WA. Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains. Pharm Pat Anal 2012;1:589-99. [PMID: 24236927 DOI: 10.4155/ppa.12.70] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
17 Bakker WA, Thomassen YE, van't Oever AG, Westdijk J, van Oijen MG, Sundermann LC, van't Veld P, Sleeman E, van Nimwegen FW, Hamidi A. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine. 2011;29:7188-7196. [PMID: 21651934 DOI: 10.1016/j.vaccine.2011.05.079] [Cited by in Crossref: 61] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
18 Thomassen YE, van Eikenhorst G, van der Pol LA, Bakker WAM. Isoelectric Point Determination of Live Polioviruses by Capillary Isoelectric Focusing with Whole Column Imaging Detection. Anal Chem 2013;85:6089-94. [DOI: 10.1021/ac400968q] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
19 Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication. Expert Rev Vaccines 2014;13:221-34. [PMID: 24308581 DOI: 10.1586/14760584.2014.864563] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
20 Baicus A. History of polio vaccination. World J Virol 2012;1:108-14. [PMID: 24175215 DOI: 10.5501/wjv.v1.i4.108] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
21 Minor PD. The polio-eradication programme and issues of the end game. J Gen Virol 2012;93:457-74. [PMID: 22128250 DOI: 10.1099/vir.0.036988-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
22 Shirato H, Someya Y, Ochiai M, Horiuchi Y, Takahashi M, Takeda N, Wakabayashi K, Ouchi Y, Ota Y, Tano Y, Abe S, Yamazaki S, Wakita T; sIPV Evaluation Group of NIID-Virology II. A national reference for inactivated polio vaccine derived from Sabin strains in Japan. Vaccine 2014;32:5163-9. [PMID: 25090648 DOI: 10.1016/j.vaccine.2014.07.065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
23 Chumakov K, Ehrenfeld E. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin Infect Dis 2008;47:1587-92. [PMID: 18990066 DOI: 10.1086/593310] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
24 Duintjer Tebbens RJ, Thompson KM. Poliovirus vaccination during the endgame: insights from integrated modeling. Expert Review of Vaccines 2017;16:577-86. [DOI: 10.1080/14760584.2017.1322514] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]